EFLM WEBINAR Laboratory diagnostic of prostate cancer 24 May 2022 at h. 18.00 CET (duration 1 h)
Speaker: Josko Osredkar (Slovenia)
Moderator: Radek Kučera (Czeck Rep)
Prostate specific antigen (PSA) is the most widely used tumor biomarker for an early detection of prostate cancer (PCa). Screening with serum PSA measurements has led to a reduction in advanced disease, however PCa specific mortality and overall mortality rates have not decreased. Moreover, overdiagnosis and overtreatment are common as a consequence of PCa screening. The limitation in specificity leads to substantial rates of false positive results of PSA test, resulting in unecessary prostate biopsies. Several biomarkers of PCa were evaluated to overcome the limitations of PSA. Free PSA and their subforms namely proPSA which is considered a promising biomarker.
Click here to register
